Section Arrow
Quote
KNSA.NASDAQ
- Kiniksa Pharmaceuticals International, plc
Quotes are at least 15-min delayed:2026/11/14 14:46 EST
Regular Hours
Last
 96.33
+0.05 (+0.05%)
Day High 
96.75 
Prev. Close
96.28 
1-M High
99.31 
Volume 
465.63K 
Bid
94.12
Ask
100
Day Low
94.505 
Open
96.37 
1-M Low
70.67 
Market Cap 
7.56B 
Currency 美元 
P/E 72.67 
%Yield -- 
10-SMA 94.05 
20-SMA 88.69 
50-SMA 81.86 
52-W High 99.31 
52-W Low 37.02 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
1.32/1.59
Enterprise Value
7.57B
Balance Sheet
Book Value Per Share
9.04
Cash Flow
Cash Flow Yield
0.02
Income Statement
Total Revenue
677.56M
Operating Revenue Per Share
3.17
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
AKANAkanda Corp.1.36+0.6883+102.47%-- 
HLNHaleon plc9.17+0.08+0.88%18.97PE
HIMSHims & Hers Health19.73------ 
TEVATeva Pharmaceutical Industries Limited44.5+0.85+1.95%102.3PE
VTRSViatris20.82+0.15+0.73%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.